Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report

Pulmonary pleomorphic carcinoma (PPC) is a rare type of non‐small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death‐1 (PD‐1), has been approved as the first‐line treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae‐Hun, Park, Sun Hyo, Hwang, Ilseon, Lee, Jin Hee, Kim, Jin Hee, Kim, Hae Won, Kim, Hyun Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580814/
https://www.ncbi.nlm.nih.gov/pubmed/34795901
http://dx.doi.org/10.1002/rcr2.875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580814/
https://www.ncbi.nlm.nih.gov/pubmed/34795901
http://dx.doi.org/10.1002/rcr2.875

Ejemplares similares